New support for replacing higher-potency ticagrelor (Brilinta) with clopidogrel as part of dual-antiplatelet therapy (DAPT) 30 days after stenting for acute myocardial infarction comes from the TALOS-AMI trial.

"A uniform, unguided de-escalation DAPT strategy switching from ticagrelor to clopidogrel was superior to the ticagrelor-based continued DAPT strategy in terms of net clinical benefit, with a significant decrease in...